MR Imaging–Based Analysis of Glioblastoma Multiforme: Estimation of IDH1 Mutation Status

References

1. 1.↵
   2. Diehn M,
   3. Nardini C,
   4. Wang DS, et al

   . Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A 2008;105:5213–18 doi:10.1073/pnas.0801279105 pmid:18362333

   Abstract/FREE Full Text
2. 2.↵
   2. Henson JW,
   3. Gaviani P,
   4. Gonzalez RG

   . MRI in treatment of adult gliomas. Lancet Oncol 2005;6:167–75 doi:10.1016/S1470-2045(05)01767-5 pmid:15737833

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Hakyemez B,
   3. Erdogan C,
   4. Bolca N, et al

   . Evaluation of different cerebral mass lesions by perfusion-weighted MR imaging. J Magn Reson Imaging 2006;24:817–24 doi:10.1002/jmri.20707 pmid:16958061

   CrossRefPubMed
4. 4.↵
   2. Calli C,
   3. Kitis O,
   4. Yunten N, et al

   . Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol 2006;58:394–403 doi:10.1016/j.ejrad.2005.12.032 pmid:16527438

   CrossRefPubMed
5. 5.↵
   2. Yamasaki F,
   3. Kurisu K,
   4. Satoh K, et al

   . Apparent diffusion coefficient of human brain tumors at MR imaging. Radiology 2005;235:985–91 doi:10.1148/radiol.2353031338 pmid:15833979

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Weber MA,
   3. Zoubaa S,
   4. Schlieter M, et al

   . Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors. Neurology 2006;66:1899–906 doi:10.1212/01.wnl.0000219767.49705.9c pmid:16801657

   Abstract/FREE Full Text
7. 7.↵
   2. Yamashita K,
   3. Yoshiura T,
   4. Hiwatashi A, et al

   . Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labeling, diffusion-weighted imaging, and ¹⁸F-fluorodeoxyglucose positron emission tomography. Neuroradiology 2013;55:135–43 doi:10.1007/s00234-012-1089-6 pmid:22961074

   CrossRefPubMed
8. 8.↵
   2. Warmuth C,
   3. Gunther M,
   4. Zimmer C

   . Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 2003;228:523–32 doi:10.1148/radiol.2282020409 pmid:12819338

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Alsop DC,
   3. Detre JA,
   4. Grossman M

   . Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Ann Neurol 2000;47:93–100 doi:10.1002/1531-8249(200001)47:1 pmid:10632106

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Chalela JA,
    3. Alsop DC,
    4. Gonzalez-Atavales JB, et al

    . Magnetic resonance perfusion imaging in acute ischemic stroke using continuous arterial spin labeling. Stroke 2000;31:680–87 doi:10.1161/01.STR.31.3.680 pmid:10700504

    Abstract/FREE Full Text
11. 11.↵
    2. Detre JA,
    3. Alsop DC,
    4. Vives LR, et al

    . Noninvasive MRI evaluation of cerebral blood flow in cerebrovascular disease. Neurology 1998;50:633–41 doi:10.1212/WNL.50.3.633 pmid:9521248

    Abstract/FREE Full Text
12. 12.↵
    2. Noguchi T,
    3. Yoshiura T,
    4. Hiwatashi A, et al

    . Perfusion imaging of brain tumors using arterial spin-labeling: correlation with histopathologic vascular density. AJNR Am J Neuroradiol 2008;29:688–93 doi:10.3174/ajnr.A0903 pmid:18184842

    Abstract/FREE Full Text
13. 13.↵
    2. Yoshiura T,
    3. Hiwatashi A,
    4. Noguchi T, et al

    . Arterial spin labelling at 3-T MR imaging for detection of individuals with Alzheimer's disease. Eur Radiol 2009;19:2819–25 doi:10.1007/s00330-009-1511-6 pmid:19588145

    CrossRefPubMed
14. 14.↵
    2. Tourdias T,
    3. Rodrigo S,
    4. Oppenheim C, et al

    . Pulsed arterial spin labeling applications in brain tumors: practical review. J Neuroradiol 2008;35:79–89 doi:10.1016/j.neurad.2007.11.007 pmid:18206239

    CrossRefPubMed
15. 15.↵
    2. Kim HS,
    3. Kim SY

    . A prospective study on the added value of pulsed arterial spin-labeling and apparent diffusion coefficients in the grading of gliomas. AJNR Am J Neuroradiol 2007;28:1693–99 doi:10.3174/ajnr.A0674 pmid:17885229

    Abstract/FREE Full Text
16. 16.↵
    2. Kono K,
    3. Inoue Y,
    4. Nakayama K, et al

    . The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol 2001;22:1081–88 pmid:11415902

    Abstract/FREE Full Text
17. 17.↵
    2. Provenzale JM,
    3. Mukundan S,
    4. Barboriak DP

    . Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology 2006;239:632–49 doi:10.1148/radiol.2393042031 pmid:16714455

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Tien RD,
    3. Felsberg GJ,
    4. Friedman H, et al

    . MR imaging of high-grade cerebral gliomas: value of diffusion-weighted echoplanar pulse sequences. AJR Am J Roentgenol 1994;162:671–77 doi:10.2214/ajr.162.3.8109520 pmid:8109520

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Higano S,
    3. Yun X,
    4. Kumabe T, et al

    . Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006;241:839–46 doi:10.1148/radiol.2413051276 pmid:17032910

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Ohgaki H,
    3. Kleihues P

    . Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170:1445–53 doi:10.2353/ajpath.2007.070011 pmid:17456751

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Ichimura K,
    3. Pearson DM,
    4. Kocialkowski S, et al

    . IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009;11:341–47 doi:10.1215/15228517-2009-025 pmid:19435942

    Abstract/FREE Full Text
22. 22.↵
    2. Myung JK,
    3. Cho HJ,
    4. Park CK, et al

    . IDH1 mutation of gliomas with long-term survival analysis. Oncol Rep 2012;28:1639–44 pmid:22922798

    PubMed
23. 23.↵
    2. Ducray F,
    3. Marie Y,
    4. Sanson M

    . IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:2248–49; author reply 2249 pmid:19469031

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Parsons DW,
    3. Jones S,
    4. Zhang X, et al

    . An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807–12 doi:10.1126/science.1164382 pmid:18772396

    Abstract/FREE Full Text
25. 25.↵
    2. Nobusawa S,
    3. Watanabe T,
    4. Kleihues P, et al

    . IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009;15:6002–07 doi:10.1158/1078-0432.CCR-09-0715 pmid:19755387

    Abstract/FREE Full Text
26. 26.↵
    2. Rohle D,
    3. Popovici-Muller J,
    4. Palaskas N, et al

    . An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013;340:626–30 doi:10.1126/science.1236062 pmid:23558169

    Abstract/FREE Full Text
27. 27.↵
    2. Kreth S,
    3. Thon N,
    4. Eigenbrod S, et al

    . O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS One 2011;6:e17156 doi:10.1371/journal.pone.0017156 pmid:21365007

    CrossRefPubMed
28. 28.↵
    2. Hegi ME,
    3. Liu L,
    4. Herman JG, et al

    . Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008;26:4189–99 doi:10.1200/JCO.2007.11.5964 pmid:18757334

    Abstract/FREE Full Text
29. 29.↵
    2. Carrillo JA,
    3. Lai A,
    4. Nghiemphu PL, et al

    . Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 2012;33:1349–55 doi:10.3174/ajnr.A2950 pmid:22322613

    Abstract/FREE Full Text
30. 30.↵
    2. Petersen ET,
    3. Lim T,
    4. Golay X

    . Model-free arterial spin labeling quantification approach for perfusion MRI. Magn Reson Med 2006;55:219–32 doi:10.1002/mrm.20784 pmid:16416430

    CrossRefPubMed
31. 31.↵
    2. Ma X,
    3. Yoshimoto K,
    4. Guan Y, et al

    . Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. Neuro Oncol 2012;14:1153–62 doi:10.1093/neuonc/nos145 pmid:22844109

    Abstract/FREE Full Text
32. 32.↵
    2. Fuller GN,
    3. Hess KR,
    4. Rhee CH, et al

    . Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol 2002;12:108–16 doi:10.1111/j.1750-3639.2002.tb00427.x pmid:11771519

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Esteller M,
    3. Garcia-Foncillas J,
    4. Andion E, et al

    . Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350–54 doi:10.1056/NEJM200011093431901 pmid:11070098

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Araki Y,
    3. Mizoguchi M,
    4. Yoshimoto K, et al

    . Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue. Brain Tumor Pathol 2011;28:25–31 doi:10.1007/s10014-010-0004-2 pmid:21249460

    CrossRefPubMed
35. 35.↵
    2. Yamashita K,
    3. Yoshiura T,
    4. Hiwatashi A, et al

    . Arterial spin labeling of hemangioblastoma: differentiation from metastatic brain tumors based on quantitative blood flow measurement. Neuroradiology 2012;54:809–13 doi:10.1007/s00234-011-0977-5 pmid:22068625

    CrossRefPubMed
36. 36.↵
    2. Lehmann P,
    3. Monet P,
    4. de Marco G, et al

    . A comparative study of perfusion measurement in brain tumours at 3 Tesla MR: arterial spin labeling versus dynamic susceptibility contrast-enhanced MRI. Eur Neurol 2010;64:21–26 doi:10.1159/000311520 pmid:20558984

    CrossRefPubMed
37. 37.↵
    2. Löbel U,
    3. Sedlacik J,
    4. Reddick WE, et al

    . Quantitative diffusion-weighted and dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging analysis of T2 hypointense lesion components in pediatric diffuse intrinsic pontine glioma. AJNR Am J Neuroradiol 2011;32:315–22 doi:10.3174/ajnr.A2277 pmid:21087935

    Abstract/FREE Full Text
38. 38.↵
    2. Loeber RT,
    3. Sherwood AR,
    4. Renshaw PF, et al

    . Differences in cerebellar blood volume in schizophrenia and bipolar disorder. Schizophr Res 1999;37:81–89 doi:10.1016/S0920-9964(98)00137-6 pmid:10227110

    CrossRefPubMedWeb of Science
39. 39.↵
    2. Sugahara T,
    3. Korogi Y,
    4. Kochi M, et al

    . Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9:53–60 pmid:10030650

    CrossRefPubMedWeb of Science
40. 40.↵
    2. DeLong ER,
    3. DeLong DM,
    4. Clarke-Pearson DL

    . Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45 doi:10.2307/2531595 pmid:3203132

    CrossRefPubMedWeb of Science
41. 41.↵
    2. Godard S,
    3. Getz G,
    4. Delorenzi M, et al

    . Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 2003;63:6613–25 pmid:14583454

    Abstract/FREE Full Text
42. 42.↵
    2. Farace P,
    3. Amelio D,
    4. Ricciardi GK, et al

    . Early MRI changes in glioblastoma in the period between surgery and adjuvant therapy. J Neurooncol 2013;111:177–85 doi:10.1007/s11060-012-0997-y pmid:23264191

    CrossRefPubMed
43. 43.↵
    2. Ohgaki H,
    3. Kleihues P

    . The definition of primary and secondary glioblastoma. Clin Cancer Res 2013;19:764–72 doi:10.1158/1078-0432.CCR-12-3002 pmid:23209033

    Abstract/FREE Full Text
44. 44.↵
    2. Homma T,
    3. Fukushima T,
    4. Vaccarella S, et al

    . Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 2006;65:846–54 doi:10.1097/01.jnen.0000235118.75182.94 pmid:16957578

    Abstract/FREE Full Text
45. 45.↵
    2. Carlson MR,
    3. Pope WB,
    4. Horvath S, et al

    . Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res 2007;13:2592–98 doi:10.1158/1078-0432.CCR-06-2772 pmid:17473188

    Abstract/FREE Full Text
46. 46.↵
    2. Lai A,
    3. Kharbanda S,
    4. Pope WB, et al

    . Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 2011;29:4482–90 doi:10.1200/JCO.2010.33.8715 pmid:22025148

    Abstract/FREE Full Text
47. 47.↵
    2. Lee S,
    3. Choi SH,
    4. Ryoo I, et al

    . Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. J Neurooncol 2015;121:141–50 doi:10.1007/s11060-014-1614-z pmid:25205290

    CrossRefPubMed
48. 48.↵
    2. Lazovic J,
    3. Soto H,
    4. Piccioni D, et al

    . Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Neuro Oncol 2012;14:1465–72 doi:10.1093/neuonc/nos258 pmid:23090985

    Abstract/FREE Full Text
49. 49.↵
    2. Kong DS,
    3. Kim ST,
    4. Kim EH, et al

    . Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. AJNR Am J Neuroradiol 2011;32:382–87 doi:10.3174/ajnr.A2286 pmid:21252041

    Abstract/FREE Full Text